Shanghai Henlius Biotech : VOLUNTARY ANNOUNCEMENT - FIRST PATIENT HAS BEEN DOSED IN A PHASE 3 CLINICAL TRIAL OF PERTUZUMAB BIOSIMILAR HLX11 (ANTI-HER2 DOMAIN II HUMANISED MONOCLONAL ANTIBODY INJECTION) FOR THE NEOADJUVANT THERAPY OF HER2-POSITIVE, HR-NEGATIVE EARLY OR LOCALLY ADVANCED BREAST CANCER IN MAINLAND CHINA
April 28, 2022 at 09:04 am EDT
Share
[title]
[date]
[link]
[market]
[doc type]
[stock code]
[stock name]
PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES, RE-ELECTION OF DIRECTORS, RE-APPOINTMENT OF AUDITORS, DECLARATION OF FINAL DIVIDEND, AMENDMENTS TO THE MEMORANDUM AND THE ARTICLES, ADOPTION OF THE AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION AND NOTICE OF ANNUAL GENERAL MEETING
28/04/2022 20:35
Link
SEHK
pdf
01652
FUSEN PHARM
(I) REMINDER ON PRECAUTIONARY MEASURES AND HYBRID MEETING ARRANGEMENTS FOR THE AGM AND THE CLASS MEETINGS AND (II) FURTHER INFORMATION ON CIRCULAR REGARDING RE-ELECTION AND APPOINTMENT OF DIRECTORS
28/04/2022 20:35
Link
SEHK
pdf
02500
VENUS MEDTECH-B
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
28/04/2022 20:34
Link
SEHK
htm
02196
FOSUN PHARMA
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING (THE "AGM") TO BE HELD ON THURSDAY, 2 JUNE 2022 AT 3:00 P.M.
28/04/2022 20:34
Link
SEHK
pdf
01940
CGII HLDGS
NOTICE OF ANNUAL GENERAL MEETING
28/04/2022 20:34
Link
SEHK
pdf
01332
TOUYUN BIOTECH
REPLY SLIP FOR H SHAREHOLDERS' CLASS MEETING TO BE HELD ON FRIDAY, 20 MAY 2022
28/04/2022 20:34
Link
SEHK
pdf
01296
GUODIAN TECH
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
28/04/2022 20:33
Link
SEHK
htm
02196
FOSUN PHARMA
MAJOR TRANSACTION IN RELATION TO THE DISPOSAL OF THE ENTIRE EQUITY INTEREST IN THE DISPOSAL COMPANY
28/04/2022 20:33
Link
SEHK
pdf
01628
YUZHOU GROUP
NOTICE OF ANNUAL GENERAL MEETING
28/04/2022 20:32
Link
SEHK
pdf
01940
CGII HLDGS
PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
28/04/2022 20:32
Link
SEHK
pdf
01725
HK AERO TECH
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
28/04/2022 20:32
Link
SEHK
htm
02196
FOSUN PHARMA
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
28/04/2022 20:31
Link
SEHK
htm
02196
FOSUN PHARMA
FORM OF PROXY FOR THE H SHAREHOLDERS' CLASS MEETING TO BE HELD ON FRIDAY, 20 MAY 2022
28/04/2022 20:30
Link
SEHK
pdf
01296
GUODIAN TECH
PROPOSED RE-ELECTION OF DIRECTORS AND PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES AND NOTICE OF ANNUAL GENERAL MEETING
28/04/2022 20:30
Link
SEHK
pdf
01940
CGII HLDGS
Notification Letter and Request Form to Non-Registered Holders
28/04/2022 20:30
Link
SEHK
pdf
01332
TOUYUN BIOTECH
REVISION OF ANNUAL CAPS FOR CONTINUING CONNECTED TRANSACTIONS
28/04/2022 20:30
Link
SEHK
pdf
02880
LIAONING PORT
An announcement has just been published by the issuer in the Chinese section of this website, a corresponding version of which may or may not be published in this section
28/04/2022 20:29
Link
SEHK
htm
02196
FOSUN PHARMA
Annual Report 2021
28/04/2022 20:28
Link
SEHK
pdf
01940
CGII HLDGS
List of Directors and their Role and Function
28/04/2022 20:28
Link
SEHK
pdf
00517
COSCO SHIP INTL
Annual Report 2021
28/04/2022 20:27
Link
SEHK
pdf
01198
ROYALE HOME
Attachments
Original Link
Original Document
Permalink
Disclaimer
Shanghai Henlius Biotech Inc. published this content on 28 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 April 2022 13:02:09 UTC.
Shanghai Henlius Biotech Inc. is a China-based company principally involved in the research, development, production and sales of monoclonal antibody products. The Companyâs main products include rituximab injection HLX01 (Hanlikang), Herceptin (trastuzumab) biosimilar HLX02, Humira (adalimumab) biosimilar HLX03 and Avastin (bevacizumab) biosimilar HLX04, as well as bio-innovative drug candidates, including HLX06 (a novel VEGFR2 inhibitor), HLX07 (an EGFR inhibitor), HLX10 (a novel PD-1 inhibitor), HLX20 (a novel PD-L1 inhibitor) and HLX22 (a novel HER2 inhibitor), among others. The Company is also engaged in the provision of related technical services. The Company operates its businesses primarily in Mainland China and the United States.
Shanghai Henlius Biotech : VOLUNTARY ANNOUNCEMENT - FIRST PATIENT HAS BEEN DOSED IN A PHASE 3 CLINICAL TRIAL OF PERTUZUMAB BIOSIMILAR HLX11 (ANTI-HER2 DOMAIN II HUMANISED MONOCLONAL ANTIBODY INJECTION) FOR THE NEOADJUVANT THERAPY OF HER2-POSITIVE, HR-NEGATIVE EARLY OR LOCALLY ADVANCED BREAST CANCER IN MAINLAND CHINA